Surrozen filings document a biotechnology issuer focused on Wnt signaling and antibody technologies for ophthalmic disease. Recent Form 8-K reports disclose operating results, financial condition, pipeline business updates for SZN-8141 and related retinal disease programs, and collaboration and license revenue tied to research milestones.
The company's regulatory reports also record governance and compensation matters, including board and executive changes and inducement equity arrangements, along with material-agreement disclosures such as the termination of the TCGFB collaboration for antibody discovery services. Cover-page data and exhibits identify Surrozen common stock and redeemable warrants as part of the public-company capital structure.
Surrozen, Inc. reports a Schedule 13G showing Point72-affiliated entities beneficially own 615,957 shares of Common Stock, representing 5.4% of the class as of April 22, 2026.
The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over these shares through Point72 Associates; Point72 Associates holds the economic interest.
Surrozen, Inc. executive Li Yang reported a charitable stock gift. As Executive Vice President of Research, Yang made a bona fide gift of 1,666 shares of Surrozen common stock on March 31, 2026, with no sale proceeds because gifts are transferred without payment.
After this donation, Yang directly holds 14,425 shares of common stock. The filing also shows indirect ownership of 351 shares held by a daughter and 351 shares held by a son, which are reported as indirect family holdings rather than direct trades in the market.
Surrozen, Inc. is calling a virtual 2026 annual stockholder meeting on May 13, 2026, to vote on key governance items. Stockholders will elect two Class II directors, ratify Ernst & Young LLP as auditor, and cast advisory votes on executive pay and how often future say‑on‑pay votes occur.
Holders of 11,486,707 common shares as of March 18, 2026 may vote online, by phone, mail, or during the live webcast. The proxy details board structure, committee memberships, and 2025 pay for top executives, including total compensation of $2,819,017 for CEO Craig Parker.
Surrozen, Inc. filed a prospectus to offer up to $50,000,000 of common stock through an at‑the‑market sales agreement with TD Securities (USA) LLC (TD Cowen). The company may sell shares from time to time on Nasdaq or other trading markets under the Sales Agreement dated March 23, 2026.
The prospectus states an assumed reference price of $25.15 per share (last reported sale price on March 20, 2026) and illustrates that up to 11,762,608 shares could be issued if the full $50,000,000 aggregate amount is sold at that price. Proceeds are intended for working capital and general corporate purposes, and TD Cowen may receive up to 3.0% of gross proceeds as compensation.
Surrozen, Inc. reported open-market share purchases by affiliated TCG Crossover funds. On March 23–24, entities associated with TCG Crossover Fund II and Fund III bought a combined 121,881 shares of Surrozen common stock in multiple open-market transactions at prices around $24.90 and $24.69 per share.
The Form 4 shows these positions as indirect holdings, with the shares held of record by TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. After these buys, the reporting entities disclose indirect ownership levels between 683,218 and 736,554 shares across the noted positions, reinforcing their status as significant, greater-than-10% shareholders.
Surrozen, Inc. files a shelf registration to offer up to $200,000,000 of securities. The registration on March 23, 2026 establishes a base prospectus that permits the company to offer common stock, preferred stock, debt securities and warrants from time to time under prospectus supplements.
The prospectus states proceeds are to be used for working capital and general corporate purposes and may be used for strategic investments or acquisitions; specific terms, prices and underwriters will be set in later prospectus supplements. Surrozen identifies itself as a smaller reporting company and notes its common stock and public warrants trade on the Nasdaq Capital Market under the symbols SRZN and SRZNW.
Surrozen, Inc. files its annual report describing a shift to an ophthalmology-focused pipeline built on Wnt-pathway modulation. The company highlights preclinical eye candidates SZN-8141 and SZN-8143 for diabetic macular edema, wet age-related macular degeneration and uveitic macular edema, all based on its SWAP antibody platform.
Surrozen’s Fzd4-targeted antibody SZN-413 is partnered with Boehringer Ingelheim; Boehringer’s 2024 advancement decision triggered a $10.0 million milestone, and a 2026 toxicology milestone entitles Surrozen to an additional $5.0 million. The company also discontinued liver candidate SZN-043 in severe alcohol-associated hepatitis to focus resources on eye diseases.
Surrozen reported a much larger 2025 net loss but ended the year with significantly more cash and a sharper focus on ophthalmology. Net loss widened to $242.0 million, or ($32.37) per share, from $63.6 million, largely due to non-cash losses tied to a 2025 private placement and related tranche and warrant liabilities.
Cash and cash equivalents rose to $89.2 million as of December 31, 2025, up from $34.6 million a year earlier, helped by equity sales and warrant exercises in early 2026. Total 2025 revenue was $3.5 million, down from $10.7 million, while research and development and general and administrative expenses increased to $29.4 million and $16.2 million, respectively. The company advanced retinal programs SZN-8141 and SZN-8143, expects to file an IND for SZN-8141 in the second half of 2026, and earned a $5.0 million milestone from Boehringer Ingelheim under the SZN-413 partnership, which also includes up to $586.5 million in potential future milestones.